试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-09-05
Icotinib Following Chemotherapy Versus Chemotherapy as Adjuvant Therapy in Stage IIA-IIIA NSCLC With EGFR Mutation
编号:NCT01996098登记状态:提前终止企业 / 申办者:Sun Yat-sen University
药物 / 成分:6-month Icotinib、12-month icotinib
登记的停止原因(原文):Slow accural.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-09-05
Dose-escalating, Safety, Tolerability and PK Study of TAS-119 in Combination With Paclitaxel in Patients With Advanced Solid Tumors
编号:NCT02134067登记状态:提前终止企业 / 申办者:Taiho Oncology, Inc.
药物 / 成分:TAS-119、Paclitaxel
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-09-05
A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or Lymphoma
编号:NCT02978235登记状态:提前终止企业 / 申办者:Taiho Oncology, Inc.
药物 / 成分:TAS4464
登记的停止原因(原文):The trial was put on Clinical Hold and subsequently terminated prior to Phase 2 due to cases of drug induced liver injury meeting the criteria for Hy's Law
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-09-05
Safety, Tolerability and Efficacy of the BL-8040 and Atezolizumab for Maintenance Treatment in Subjects With Acute Myeloid Leukemia (AML)
编号:NCT03154827登记状态:提前终止企业 / 申办者:BioLineRx, Ltd.
药物 / 成分:BL-8040、Atezolizumab
登记的停止原因(原文):Due to lack of enrollment
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-09-05
A Study of TAS0728 in Patients With Solid Tumors With HER2 or HER3 Abnormalities
编号:NCT03410927登记状态:提前终止企业 / 申办者:Taiho Oncology, Inc.
药物 / 成分:TAS0728
登记的停止原因(原文):The study was stopped due to unacceptable toxicity during the dose-escalation portion (Phase 1) of the study and did not progress to Phase 2
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-09-05
Baclofen as a Perioperative Analgesic Adjuvant
编号:NCT03720717登记状态:提前终止企业 / 申办者:University of Alabama at Birmingham
药物 / 成分:Baclofen 10mg、Placebo
登记的停止原因(原文):Futility analysis at midpoint analysis
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-09-05
Effect of NSAID Use on Pain and Opioid Consumption Following Distal Radius Fracture
编号:NCT03749616登记状态:提前终止企业 / 申办者:University of Missouri-Columbia
药物 / 成分:Ibuprofen、Acetaminophen
登记的停止原因(原文):Original principal investigator left the institution and investigator replacing him did not have the patient population to enroll as needed.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-09-05
Study of the Safety of Therapeutic Treatment With an Immunomodulatory Agent (N-803) in Adults With COVID-19
编号:NCT04385849登记状态:提前终止企业 / 申办者:ImmunityBio, Inc.
药物 / 成分:N-803、Saline
登记的停止原因(原文):Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-09-05
Study of the Safety of Therapeutic Tx With Immunomodulatory MSC in Adults With COVID-19 Infection Requiring Mechanical Ventilation
编号:NCT04397796登记状态:提前终止企业 / 申办者:ImmunityBio, Inc.
药物 / 成分:BM-Allo.MSC、Placebo
登记的停止原因(原文):Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-09-05
Post-operative Course of Dexamethasone to Reduce Tonsillectomy Morbidity
编号:NCT04879823登记状态:提前终止企业 / 申办者:David Chi, MD
药物 / 成分:Dexamethasone、Ibuprofen、Acetaminophen、Placebo
登记的停止原因(原文):slow recruitment
查看官方原始记录 ↗